Serology Testing Market Revenue Trends and Growth Potential 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Serology Testing Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments, Software & Services), by Service (Infectious Disease Serology, Autoimmune Disease Serology, Allergy Serology, Immunohematology Serology, Transplantation & Histocompatibility Serology, Other Clinical Serology Testing), by Format (Laboratory-Based Serology Testing, Rapid Point-of-Care Serology Testing), by Technology (Chemiluminescent Immunoassay, Enzyme Immunoassay, Fluorescence-Based Immunoassay, Immunofluorescence Assay, Rapid Immunochromatographic Assay, Agglutination-Based Assay, Immunoblot & Line Immunoassay, Multiplex Bead & Array-Based Immunoassay, Other Commercial Serological Technologies), by End Use (Hospitals & Hospital-Based Laboratories, Independent Diagnostic & Reference Laboratories, Blood Banks, Blood Centres & Transfusion Laboratories, Public Health & Government Laboratories, Physician Offices, Clinics & Point-of-Care Facilities, Other End Users),-Market Outlook And Industry Analysis 2035"

Serology Testing Market Size is valued at USD 17.13 Bn in 2025 and is predicted to reach USD 33.69 Bn by the year 2035 at a 7.2% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com//request-sample/3769

Serology testing has now become an essential element of modern healthcare, helping to evaluate immune responses and to identify antibodies and antigens associated with various diseases in a wide range of clinical situations. Its use goes well beyond that of diagnosing infectious diseases to cover autoimmune and allergic disorders, immunohematology, issues relating to transplant compatibility, and other specialized clinical examinations. Since healthcare systems are having to deal with ever more complex diagnostic needs, there has been an increasing demand for reliable serological evidence-especially in cases where a clinical assessment has to be backed by information regarding previous exposure, immune status, or compatibility. To meet these demands, testing solutions must combine analytical reliability with operational efficiency and accessibility for use in different types of healthcare settings.

The market is advancing as a result of ongoing technological development and because serological testing is being more and more incorporated into standard diagnostic procedures. Better immunoassay platforms, automated laboratory processes, and rapid testing methods are enabling healthcare providers to carry out and make use of serological evaluations in more ways.

The fact that serological testing is being adopted in central laboratories, in decentralized testing situations, and in specialist clinical facilities is opening up opportunities for both existing diagnostic technologies and for more recent testing methods. Since diagnostic infrastructure is changing in healthcare systems all over the world, serology testing now offers a growing range of possibilities due to the modernisation of clinical testing, the wider range of diagnostic uses, and the increasing significance of timely, evidence-based medical decision-making.

List of Prominent Players in the Serology Testing Market:
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Danaher Corporation
• QuidelOrtho Corporation
• Bio-Rad Laboratories, Inc.
• Grifols, S.A.
• Siemens Healthineers AG
• bioMérieux SA
• DiaSorin S.p.A.
• Thermo Fisher Scientific Inc.

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

Market Dynamics:
Drivers:
The market for serology testing is due to the continuing burden of infectious diseases, the rising prevalence of autoimmune and allergic disorders, the growing demand for blood screening and transfusion safety, and technological progress in immunoassay systems. The requirement to identify infections such as HIV, hepatitis, and syphilis means that routine serological testing is carried out in hospitals, diagnostic laboratories, antenatal care centres, and blood banks. At the same time, the greater demand for the diagnosis of autoimmune conditions and allergic disorders is leading to an increased use of antibody assays specific to these diseases and of specialised diagnostic panels.

The focus on blood safety also maintains the demand for screening for infectious diseases, for blood group typing and for compatibility testing in order to reduce the risks associated with transfusions. Furthermore, progress in enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, automation, and multiplex testing is enhancing testing efficiency, analytical consistency, and the capacity to process samples, prompting laboratories to upgrade their diagnostic equipment and expand their serological testing abilities.

Challenges:
The market for serology testing encounters a number of difficulties, such as problems with diagnostic accuracy, the high cost of sophisticated testing systems, the difficulty of identifying infections in their early stages, and the need to meet regulatory requirements. Differences in the sensitivity and specificity of the tests can cause false-positive or false-negative results as a result of cross-reactivity or because of inadequate antibody levels, which may mean that further testing is needed and make clinical interpretation more difficult.

The large initial outlay required for diagnostic equipment, laboratory facilities, maintenance, and quality-control measures can also hinder the introduction of advanced testing systems, especially in smaller laboratories and in healthcare facilities with limited resources. Moreover, antibody-based tests may not be able to detect some infections in the early stages, prior to the immune response having developed sufficiently, thus making it necessary to use other diagnostic methods or carry out repeated testing.

Regional Trends:
North America holds a leading role in the serology testing market due to its robust diagnostic research ecosystem, well-established reimbursement arrangements, and the way laboratory testing is incorporated into regular clinical decision-making. The region has a well-developed laboratory infrastructure together with set testing protocols that enable the use of serological assays for disease monitoring, the evaluation of autoimmune disorders, allergy testing, and assessing transplant compatibility. Cooperation between diagnostic companies, healthcare providers, academic institutions, and research organisations helps to promote the development and uptake of specialized testing solutions.

Moreover, the presence of skilled laboratory personnel, existing quality-control procedures, and the demand for reliable diagnostic results all contribute to the acceptance of automated and high-throughput testing systems. Ongoing investment in the modernisation of laboratories and the expansion of specialised diagnostic services further supports growth in the regional market, thus strengthening North America's status as a major market for serology testing.

Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3769

Key Development
• January 2026: DiaSorin received FDA De Novo authorization for its automated total anti-HDV diagnostic test on the LIAISON XL immunoassay system. Supported by Gilead Sciences, the test aids in detecting hepatitis delta virus (HDV) co-infection and superinfection in patients with hepatitis B, enabling standardized diagnosis and improved clinical management.

Segmentation of Serology Testing Market-
By Product -
• Reagents & Consumables
• Instruments
• Software & Services
By Services -
• Infectious Disease Serology
• Autoimmune Disease Serology
• Allergy Serology
• Immunohematology Serology
• Transplantation & Histocompatibility Serology
• Other Clinical Serology Testing
By Format -
• Laboratory-Based Serology Testing
• Rapid Point-of-Care Serology Testing
By Technology -
• Chemiluminescent Immunoassay
• Enzyme Immunoassay
• Fluorescence-Based Immunoassay
• Immunofluorescence Assay
• Rapid Immunochromatographic Assay
• Agglutination-Based Assay
• Immunoblot & Line Immunoassay
• Multiplex Bead & Array-Based Immunoassay
• Other Commercial Serological Technologies
By End Use -
• Hospitals & Hospital-Based Laboratories
• Independent Diagnostic & Reference Laboratories
• Blood Banks, Blood Centres & Transfusion Laboratories
• Public Health & Government Laboratories
• Physician Offices, Clinics & Point-of-Care Facilities
• Other End Users
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/serology-testing-market/3769

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.